A case of delayed severe hypersensitivity reaction during Genexol-PM® infusion

Hyun Kyung Kim, Su Woo Kim, Hye Won Kang, Kyoung Joo Kwon, Hye Sung Park, Yon Ju Ryu, Jin Hwa Lee, Eun Mi Chun, Young Joo Cho, Jung Hyun Chang

Research output: Contribution to journalArticlepeer-review


Although Taxol® is one of the most successful drugs in current cancer chemotherapy against solid tumors, a major problem is hypersensitivity reactions that arises as a consequence of activation of the complement (C) system, "C activation-related pseudo-allergy". Most severe hypersenstivity reactions occur within the first few minutes of Taxol® administration, usually after the first or second dose. Here we report a case of a severe hypersensitivity reaction in a 72-year-old man undergoing Genexol-PM® infusion. Hypotension and polymorphic pruritic skin rash appeared 2 hours after the start of Genexol-PM® infusion (with an appropriate premedication). Treating with methylprednisolone, epinephrine and inotropic agents, reduced the hypotension and the skin rash disappeared. We report this case with a review of the literature. Copyright

Original languageEnglish
Pages (from-to)294-297
Number of pages4
JournalTuberculosis and Respiratory Diseases
Issue number5
StatePublished - May 2010


  • Anaphylaxis
  • Hypersensitivity, delayed
  • Paclitaxel
  • Purpura


Dive into the research topics of 'A case of delayed severe hypersensitivity reaction during Genexol-PM® infusion'. Together they form a unique fingerprint.

Cite this